These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

417 related articles for article (PubMed ID: 27519791)

  • 1. PNA clamping-assisted fluorescence melting curve analysis for detecting EGFR and KRAS mutations in the circulating tumor DNA of patients with advanced non-small cell lung cancer.
    Han JY; Choi JJ; Kim JY; Han YL; Lee GK
    BMC Cancer; 2016 Aug; 16():627. PubMed ID: 27519791
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prospective Validation of Rapid Plasma Genotyping for the Detection of EGFR and KRAS Mutations in Advanced Lung Cancer.
    Sacher AG; Paweletz C; Dahlberg SE; Alden RS; O'Connell A; Feeney N; Mach SL; Jänne PA; Oxnard GR
    JAMA Oncol; 2016 Aug; 2(8):1014-22. PubMed ID: 27055085
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Clinical implications of the concentration and EGFR/KRAS mutations of plasma cell free DNA of patients with lung cancer and esophageal cancer].
    Zhang R; Li Y; Chen Y; Liu X; Wang Z; Sun H; Zheng Y; Ding Z; Lan L; Li M; Qin J; Chen X
    Zhonghua Yi Xue Za Zhi; 2015 Dec; 95(47):3839-42. PubMed ID: 27337801
    [TBL] [Abstract][Full Text] [Related]  

  • 4. EGFR and KRAS mutation status in non-small-cell lung cancer occurring in HIV-infected patients.
    Créquit P; Ruppert AM; Rozensztajn N; Gounant V; Vieira T; Poulot V; Antoine M; Chouaid C; Wislez M; Cadranel J; Lavole A
    Lung Cancer; 2016 Jun; 96():74-7. PubMed ID: 27133754
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Detection and comparison of EGFR mutations in matched tumor tissues, cell blocks, pleural effusions, and sera from patients with NSCLC with malignant pleural effusion, by PNA clamping and direct sequencing.
    Yeo CD; Kim JW; Kim KH; Ha JH; Rhee CK; Kim SJ; Kim YK; Park CK; Lee SH; Park MS; Yim HW
    Lung Cancer; 2013 Aug; 81(2):207-12. PubMed ID: 23726527
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Using whole genome amplification (WGA) of low-volume biopsies to assess the prognostic role of EGFR, KRAS, p53, and CMET mutations in advanced-stage non-small cell lung cancer (NSCLC).
    Lim EH; Zhang SL; Li JL; Yap WS; Howe TC; Tan BP; Lee YS; Wong D; Khoo KL; Seto KY; Tan L; Agasthian T; Koong HN; Tam J; Tan C; Caleb M; Chang A; Ng A; Tan P
    J Thorac Oncol; 2009 Jan; 4(1):12-21. PubMed ID: 19096301
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of EGFR signaling pathway somatic DNA mutations derived from peripheral blood and corresponding tumor tissue of patients with advanced non-small-cell lung cancer using liquidchip technology.
    Zhang H; Liu D; Li S; Zheng Y; Yang X; Li X; Zhang Q; Qin N; Lu J; Ren-Heidenreich L; Yang H; Wu Y; Zhang X; Nong J; Sun Y; Zhang S
    J Mol Diagn; 2013 Nov; 15(6):819-26. PubMed ID: 23988622
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association of EGFR L858R Mutation in Circulating Free DNA With Survival in the EURTAC Trial.
    Karachaliou N; Mayo-de las Casas C; Queralt C; de Aguirre I; Melloni B; Cardenal F; Garcia-Gomez R; Massuti B; Sánchez JM; Porta R; Ponce-Aix S; Moran T; Carcereny E; Felip E; Bover I; Insa A; Reguart N; Isla D; Vergnenegre A; de Marinis F; Gervais R; Corre R; Paz-Ares L; Morales-Espinosa D; Viteri S; Drozdowskyj A; Jordana-Ariza N; Ramirez-Serrano JL; Molina-Vila MA; Rosell R;
    JAMA Oncol; 2015 May; 1(2):149-57. PubMed ID: 26181014
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Peptide Nucleic Acid Clamping Versus Direct Sequencing for the Detection of EGFR Gene Mutation in Patients with Non-small Cell Lung Cancer.
    Yoon SH; Choi YD; Oh IJ; Kim KS; Choi H; Chang J; Shin HJ; Park CK; Kim YC
    Cancer Res Treat; 2015 Oct; 47(4):661-9. PubMed ID: 25715768
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of systematic EGFR and KRAS mutation evaluation on progression-free survival and overall survival in patients with advanced non-small-cell lung cancer treated by erlotinib in a French prospective cohort (ERMETIC project--part 2).
    Cadranel J; Mauguen A; Faller M; Zalcman G; Buisine MP; Westeel V; Longchampt E; Wislez M; Coudert B; Daniel C; Chetaille B; Michiels S; Blons H; Solassol J; De Fraipont F; Foucher P; Urban T; Lacroix L; Poulot V; Quoix E; Antoine M; Danton G; Morin F; Chouaid C; Pignon JP
    J Thorac Oncol; 2012 Oct; 7(10):1490-502. PubMed ID: 22982650
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Potential clinical significance of a plasma-based KRAS mutation analysis in patients with advanced non-small cell lung cancer.
    Wang S; An T; Wang J; Zhao J; Wang Z; Zhuo M; Bai H; Yang L; Zhang Y; Wang X; Duan J; Wang Y; Guo Q; Wu M
    Clin Cancer Res; 2010 Feb; 16(4):1324-30. PubMed ID: 20145159
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phosphoinositide-3-kinase catalytic alpha and KRAS mutations are important predictors of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in patients with advanced non-small cell lung cancer.
    Ludovini V; Bianconi F; Pistola L; Chiari R; Minotti V; Colella R; Giuffrida D; Tofanetti FR; Siggillino A; Flacco A; Baldelli E; Iacono D; Mameli MG; Cavaliere A; Crinò L
    J Thorac Oncol; 2011 Apr; 6(4):707-15. PubMed ID: 21258250
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of a fast and fully automated platform to diagnose
    Lambros L; Caumont C; Guibourg B; Barel F; Quintin-Roué I; Marcorelles P; Merlio JP; Uguen A
    J Clin Pathol; 2017 Jun; 70(6):544-549. PubMed ID: 28153953
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Relationship between driver gene mutations, their relative protein expressions and survival in non-small cell lung carcinoma in Macao.
    Chan KI; Vong HT; Sin LF; Yip YC; Zhong XY; Wen JM
    Clin Respir J; 2018 Apr; 12(4):1416-1423. PubMed ID: 28756651
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of EGFR mutation status between plasma and tumor tissue in non-small cell lung cancer using the Scorpion ARMS method and the possible prognostic significance of plasma EGFR mutation status.
    Duan H; Lu J; Lu T; Gao J; Zhang J; Xu Y; Wang M; Wu H; Liang Z; Liu T
    Int J Clin Exp Pathol; 2015; 8(10):13136-45. PubMed ID: 26722512
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of PNA clamping and direct sequencing for detecting KRAS mutations in matched tumour tissue, cell block, pleural effusion and serum from patients with malignant pleural effusion.
    Kang JY; Park CK; Yeo CD; Lee HY; Rhee CK; Kim SJ; Kim SC; Kim YK; Park MS; Yim HW
    Respirology; 2015 Jan; 20(1):138-46. PubMed ID: 25302858
    [TBL] [Abstract][Full Text] [Related]  

  • 17. FDG uptake in non-small cell lung cancer is not an independent predictor of EGFR or KRAS mutation status: a retrospective analysis of 206 patients.
    Lee SM; Bae SK; Jung SJ; Kim CK
    Clin Nucl Med; 2015 Dec; 40(12):950-8. PubMed ID: 26359571
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cross-validation study for epidermal growth factor receptor and KRAS mutation detection in 74 blinded non-small cell lung carcinoma samples: a total of 5550 exons sequenced by 15 molecular French laboratories (evaluation of the EGFR mutation status for the administration of EGFR-TKIs in non-small cell lung carcinoma [ERMETIC] project--part 1).
    Beau-Faller M; Degeorges A; Rolland E; Mounawar M; Antoine M; Poulot V; Mauguen A; Barbu V; Coulet F; Prétet JL; Bièche I; Blons H; Boyer JC; Buisine MP; de Fraipont F; Lizard S; Olschwang S; Saulnier P; Prunier-Mirebeau D; Richard N; Danel C; Brambilla E; Chouaid C; Zalcman G; Hainaut P; Michiels S; Cadranel J
    J Thorac Oncol; 2011 Jun; 6(6):1006-15. PubMed ID: 21532509
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Detection and comparison of peptide nucleic acid-mediated real-time polymerase chain reaction clamping and direct gene sequencing for epidermal growth factor receptor mutations in patients with non-small cell lung cancer.
    Kim HJ; Lee KY; Kim YC; Kim KS; Lee SY; Jang TW; Lee MK; Shin KC; Lee GH; Lee JC; Lee JE; Kim SY
    Lung Cancer; 2012 Mar; 75(3):321-5. PubMed ID: 21930325
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Assessment of EGFR and KRAS mutation status from FNAs and core-needle biopsies of non-small cell lung cancer.
    Lozano MD; Labiano T; Echeveste J; Gurpide A; Martín-Algarra S; Zhang G; Sharma A; Palma JF
    Cancer Cytopathol; 2015 Apr; 123(4):230-6. PubMed ID: 25529460
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.